Fabiana Perna
@fabianaperna
Followers
1K
Following
8K
Statuses
1K
Joined April 2012
My NCI MERIT (R37) award just started (5+2 years of funds) and thus, I would like to invite smart and motivated scientists who are interested in translational research and cutting-edge technologies to apply for a position in my lab. Cool science and good quality of life. Email me
4
21
63
Good morning San Diego! I am simply thrilled to speak at the Scientific Program Session PROTEO-GENOMICS TO BETTER STUDY MULTIPLE MYELOMA BIOLOGY AND EVOLUTION Saturday, December 7, 2024, 9:30 a.m. - 10: 45 a.m. Marriott Marquis San Diego Marina, San Diego Ballroom AB.
0
0
9
RT @ASGCTherapy: TOMORROW at 1 p.m. CT: Join us for an in-depth webinar (FREE for ASGCT Members) that delves into the fascinating world of…
0
1
0
It was great to speak today at the 86th Japanese Society of Hematology annual meeting! Exceptional hospitality to @ASH_hematology delegates. Arigatō Goizamasu #JSH2024 🙏🇯🇵 @MoffittNews
0
0
11
RT @YiLinMDPhD: US #mmsm Immunotherapy Consortium data on cilta-cel #CART in standard of care practice. Strong work by all the investigator…
0
12
0
RT @ASGCTherapy: NEW @MolTherapy issue is out now! (It's a special issue on novel therapeutic targets + biomarker development!) On the cove…
0
1
0
RT @BloodAdvances: Beyond BCMA: newer immune targets in myeloma #immunobiologyandimmunotherapy #lymphoidneoplasia h…
0
21
0
RT @BloodAdvances: CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
0
26
0
Excited to share our newest paper on the mass spectrometry based strategies for mapping the cancer surface proteome in search of novel target antigens @MolTherapy @MoffittNews
Mapping the cancer surface proteome in search of target antigens for immunotherapy #genetherapy #celltherapy
1
2
21
RT @ASH_hematology: Join us June 28 at 11:00 a.m. ET for Strategies for Success in Academic Careers: From Box to Bench: How to Set up the L…
0
9
0
Excited to share our paper on novel toxicities of CAR T cell therapy @BloodAdvances @ParekSam @CarolineDiorio @MelodySmithMD @MSubklewe Rakesh Mehta @DrFredLocke @NiraliShahMD
1
12
50
Age of Principal Investigators at the Time of First R01-Equivalent Remains Level with Recent Years in FY 2023 – NIH Extramural Nexus
0
0
3
RT @Vuphuongly: mRNA-based therapeutic strategies for cancer treatment: Molecular Therapy @ThilelliTaibi @fabianaperna
0
2
0
RT @Vuphuongly: Want to learn about mRNA based cancer therapy?! Check out our review on RNA design, LNPs and notable clinical developments…
0
1
0
Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression | Nature Communications
1
1
17
RT @MolTherapy: CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment
0
8
0